{
    "symbol": "NUWE",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-09 15:39:20",
    "content": " Thank you for joining today's conference call to discuss Nuwellis' corporate developments and financial results for the second quarter ended June 30, 2022. You should review the cautionary statements and discussions of risk factors included in the company's press release issued today, the company's latest 10-K, the subsequent reports as well as its other filings with the Securities and Exchange Commission under the titles Risk Factors or Cautionary Statements related to forward-looking statements for additional discussion of risk factors that could cause actual results to differ materially from management's current expectations. Eleven years ago when Meredith was getting her Master's degree in nursing, she studied the results of using the Aquadex therapy in her hospital and published a 0% readmission for heart failure patients resistant to diuretics. Revenue for the second quarter came in at $2.2 million, representing 15% sequential growth from the first quarter of 2022, however, down compared to the second record-setting prior year second quarter. Revenue for the second quarter was $2.2 million, representing 15% sequential growth from the first quarter of 2022 and down 12% compared to the prior year period. In terms of the performance by customer segment, Critical Care and Pediatrics posted strong growth versus the prior quarter, fueled by higher console sales and also increased utilization of our disposable circuits in some accounts."
}